We measured phospholipase A2 (PLA2; EC 3.1.1.4) activity in normal and uremic plasma, using [1-14CJoIeate-Iabeled autoclaved Escherichia coil as substrate. Hydrolysis of bactenal phospholipid by crude plasma from both groups was optimal at pH 5.5, was specific for the 2-acyl position of phospholipids, and had an absolute requirement for calcium. Activity was greatest in the presence of added Ca2, 5 mmol/L, but this increase was inhibited by several divalent cations(Mg2, Zn2, Cu2, Ba2, Co2, 2± Fe2) and by Fe3. PLA2 activity was also inhibited by hepann at acid and alkaline pH, normal plasma being more sensitive than uremic plasma to this inhibition. Enzyme activity in undiluted plasma was eightfold greater in uremic than in normal plasma. Dilution of plasma by two to fourfold increased the total activity of both normal and uremic plasma. However, the relative differences in total activity between the groups remained constant (eight-to 11-fold). The cause and consequences of the increased PLA2 activity in uremia remain to be established.
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Phospholipase
A2 activity (PLA2; EC 3.1.1.4) has been described in serum and plasma of humans (1) (2) (3) , as well as in rats (2,4), rabbits (1), and other species (2). This enzyme, which acts on the 2-position of phospholipids to liberate predominately cis-unsaturated fatty acids and lysophospholipids, plays an important role in the turnover of membrane phospholipids, the digestion of foreign agents such as bacteria and viruses, and the release of arachidonic acid for eicosanoid synthesis (5). Lysophospholipids released by PLA2 hydrolysis are cytotoxic, and activity of PLA2 in human plasma is significantly increased in pancreatitis (6, 7) and in Gram-negative septic shock (8) . PLA2 activity is markedly increased in serum and synovial fluid of patients with rheumatoid arthritis and osteoarthritis (9). Because of the postulated role of PLA2 in inflammation and cytoxicity as well as in other diverse physiological and pathological processes, we have studied PLA2 activity in normal plasma and in plasma from patients with renal failure.
Materials and Methods
We studied 52 patients with chronic renal failure who were to fatty acids and phospholipid were scraped into counting vials containing 10 mL of scintillation fluid for determination of radioactivity. The radioactivity was counted in a scintillation counter and the disintegrations per minute were determined by quench correction. We express PLA2 activity as percent hydrolysis or micromoles of phospholipid hydrolyzed per minute per liter at 37 #{176}C.
Results
PLA2 activity in both normal and uremic human plasma was greatest at pH 5.5 in the presence of added CaCl2, 5 mmol/L. The activity nearly became constant when 15% to 20% of the substrate was hydrolyzed (Figure 1) . The same pH optimum was found when we used the following buffers: 50 mmol!L (sodium acetate, pH 3.5-5.5; Tris maleate, pH 5.5-7.0; Bis-Tris, pH 6.5-8.0; and Tris hydrochloride, pH 7.0-9.0). At calcium concentrations >5 mmol/L, plasma PLA2 activity was inhibited. Other mono-, di-, and trivalent metal ions did not support enzymatic activity in the absence of added Ca2 and generally inhibited activity in the presence of the added Ca2 (Table 1) . Oleic and linoleic acid, 50 moLfL, and end products from hydrolysis of E. coli phospholipid substrate did not inhibit plasma PLA2 activity. Heparin more effectively inhibited PLA2 in normal plasma than in uremic plasma at pH 5.5 ( Figure 2 ). PLA2 activity was also inhibited in both samples by heparin at neutral to alkaline pH, although PLA2 isolated from human synovial fluid and optimally active at pH 7.0 in the presence of Ca2 ± was unaffected by heparin. Table 2 
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Fe2 NIL Fe3 CO2 Pb2 that PLA2 activity in uremic plasma is eightfold that in normal plasma. Moreover, when plasma from either source was diluted, the apparent activity in both plasma samples increased by two-to fourfold, but the difference in relative activity remained essentially the same. At dilutions of 10-and 25-fold, PLA2 activity in uremic plasma was 10 and 11.5 times that of normal plasma. The total plasma protein concentration was not significantly different between the two groups (controls, 58.4 ± 3.0 gIL; uremics, 61.1 ± 7.0; mean ± SD), so these results cannot be explained simply by altered protein concentrations.
Our results demonstrate that PLA2 activity is markedly increased in uremic plasma. Phospholipase A activity in plasma of normal and uremic subjects was specific for deacylation of the 2 position, because incubations with 1-[1-14C]stearoyl-2-acylglycero-3-phosphoethanolamine generated 1-[1-'4Clstearoyl-lysophosphatidylethanolamine as the only radioactive product. The enzyme has an absolute requirement for Ca2, and the activity is not supported by other metal ions, is totally abolished by EDTA, and is inhibited by heparin. These properties are characteristic of many PLA2 enzymes studied to date (2, 11, 14) . With the exception of lysosomal and polymorphonuclear enzymes (5, 11), PLA2 from other manininlian sources generally has pH optima in the pH range 7.5-9.0. In contrast, we found that PLA2 of normal and uremic plasma was optimally active at 5.5. This acidic pH optimum for a Ca2-dependent PLA2 is unusual, but we have found a similar pH optimum (pH 5.0-6.0) for PLA2 activity in rat plasma.
Intravenous administration of heparin to rat (15, 16) or man (17) causes release of PLA2 from liver (16); thus the human plasma enzyme could be of hepatic origin. However, in the heparin-treated rat the enzyme has a pH optimum of 9.5, is more heat labile, and is not inhibited by heparun, 10 kU/L (15) , in contrast to the PLA2 in human plasma. Evidently, the PLA2 described here is a different enzyme and may not be of hepatic origin.
PLA2 activity not only is increased eightfold in uremia (Table 2) but also is less sensitive to inhibition by heparin; 2 USP units of heparin per milliliter results in 53% inhibition of PLA2 from normal plasma vs only 8% for PLA2 from uremic plasma (Figure 2) . The increased enzyme activity in uremia is not ascribable to a change in protein concentration; the value for total plasma protein was not significantly different between the two groups.
In addition, we found a 4.3-fold increase in PLA2 activity when uremic plasma was diluted 10-to 25-fold with distilled water (Table 2) . Thus, dilution increases the measurable enzymic activity, although the mechanism of this is unclear. Results of some studies (18, 19) suggest that human plasma PLA2 exists as a pro-enzyme and that treatment with trypsin converts it to a more active form. More recently Miwa et al. (20) have demonstrated that trypsin increases PLA2 activity by degrading a high-molecular-mass lipoprotein inhibitor of PLA2 in plasma. Thus, the increased plasma activity on dilution may also be a result of altered enzyme-inhibitor interactions. The kidney is a major site for catabolism of peptides of molecular mass <25 000 Da (21,22). In the case of plasma PLA2 with a reported molecular mass of 14 000 Da (8), renal degradation may play an important role in controlling its concentration. Consequently, the large increases in PLA2 activity in chronic renal failure may result, at least in part, from decreased renal catabolism. Yet bilateral nephrectomy in rats did not alter plasma PLA2 activity during the first 48 h after nephrectomy (4). Moreover, PLA2 activity in plasma and serum is increased in a variety of pathological diseases where renal function was not compromised (6) (7) (8) (9) 23) .
Further study is required to clarify what role, if any, the kidneys play in controlling plasma PLA2 concentration and whether its increased activity contributes to the pathology of chronic renal failure.
